1250 related articles for article (PubMed ID: 14607757)
1. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
Lillicrap D; Poon MC; Walker I; Xie F; Schwartz BA;
Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
Dunkley S; Baker RI; Pidcock M; Price J; Seldon M; Smith M; Street A; Maher D; Barrese G; Stone C; Lloyd J
Haemophilia; 2010 Jul; 16(4):615-24. PubMed ID: 20331755
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
Federici AB; Barillari G; Zanon E; Mazzucconi MG; Musso R; Targhetta R; Mannucci PM
Haemophilia; 2010 Jan; 16(1):101-10. PubMed ID: 19811543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety during formulation switch of a pasteurized VWF/FVIII concentrate: results from an Italian prospective observational study in patients with von Willebrand disease.
Castaman G; Coppola A; Zanon E; Boeri E; Musso M; Siragusa S; Federici AB; Mancuso G; Barillari G; Biasoli C; Feola G; Franchini M; Moratelli S; Gamba G; Schinco P; Valdrè L; Dragani A; Mazzucconi G; Tagliaferri A; Morfini M
Haemophilia; 2013 Jan; 19(1):82-8. PubMed ID: 22957493
[TBL] [Abstract][Full Text] [Related]
7. Successful surgical haemostasis in patients with von Willebrand disease with Koate DVI.
Viswabandya A; Mathews V; George B; Nair SC; Baidya S; Mammen JJ; Chandy M; Srivastava A
Haemophilia; 2008 Jul; 14(4):763-7. PubMed ID: 18445014
[TBL] [Abstract][Full Text] [Related]
8. Haemate P/Humate-P for the treatment of von Willebrand disease: considerations for use and clinical experience.
Auerswald G; Kreuz W
Haemophilia; 2008 Nov; 14 Suppl 5():39-46. PubMed ID: 18786009
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
Hernandez-Navarro F; Quintana M; Jimenez-Yuste V; Alvarez MT; Fernandez-Morata R
Haemophilia; 2008 Sep; 14(5):963-7. PubMed ID: 18624696
[TBL] [Abstract][Full Text] [Related]
10. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
Berntorp E; Windyga J;
Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
[TBL] [Abstract][Full Text] [Related]
11. Clinical use of Haemate P in inherited von Willebrand's disease: a cohort study on 100 Italian patients.
Federici AB; Castaman G; Franchini M; Morfini M; Zanon E; Coppola A; Tagliaferri A; Boeri E; Mazzucconi MG; Rossetti G; Mannucci PM
Haematologica; 2007 Jul; 92(7):944-51. PubMed ID: 17606445
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
Windyga J; von Depka-Prondzinski M;
Thromb Haemost; 2011 Jun; 105(6):1072-9. PubMed ID: 21437358
[TBL] [Abstract][Full Text] [Related]
13. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a high purity, double virus inactivated factor VIII/von Willebrand factor concentrate (Biostate) in patients with von Willebrand disorder requiring invasive or surgical procedures.
Shortt J; Dunkley S; Rickard K; Baker R; Street A
Haemophilia; 2007 Mar; 13(2):144-8. PubMed ID: 17286766
[TBL] [Abstract][Full Text] [Related]
15. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
[TBL] [Abstract][Full Text] [Related]
16. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
17. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
18. Long-term prophylaxis with intermediate-purity factor VIII concentrate (Haemate P) in a patient with type 3 von Willebrand disease and recurrent gastrointestinal bleeding.
Coppola A; Cimino E; Conca P; De Simone C; Tufano A; Tarantino G; Cerbone AM; Minno G
Haemophilia; 2006 Jan; 12(1):90-4. PubMed ID: 16409182
[TBL] [Abstract][Full Text] [Related]
19. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
[TBL] [Abstract][Full Text] [Related]
20. Fanhdi, efficacy and safety in von Willebrand's disease: prospective international study results.
Bello IF; Yuste VJ; Molina MQ; Navarro FH
Haemophilia; 2007 Dec; 13 Suppl 5():25-32. PubMed ID: 18078394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]